Columbus Circle Investors boosted its position in shares of Neurocrine Biosciences (NASDAQ:NBIX) by 18.0% in the first quarter, Holdings Channel reports. The institutional investor owned 376,326 shares of the company’s stock after acquiring an additional 57,520 shares during the quarter. Columbus Circle Investors’ holdings in Neurocrine Biosciences were worth $31,209,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. American International Group Inc. bought a new stake in Neurocrine Biosciences during the 4th quarter valued at $161,000. M&T Bank Corp purchased a new position in Neurocrine Biosciences during the 4th quarter valued at $202,000. Mission Wealth Management LP purchased a new position in Neurocrine Biosciences during the 4th quarter valued at $204,000. Vident Investment Advisory LLC purchased a new position in Neurocrine Biosciences during the 4th quarter valued at $207,000. Finally, CIBC Asset Management Inc purchased a new position in Neurocrine Biosciences during the 4th quarter valued at $230,000.
A number of research analysts have issued reports on NBIX shares. BidaskClub raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. Oppenheimer set a $100.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, February 14th. Barclays reissued an “overweight” rating and set a $100.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, February 14th. JPMorgan Chase boosted their price objective on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. Finally, Deutsche Bank boosted their price objective on shares of Neurocrine Biosciences to $97.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Thirteen investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $102.77.
NASDAQ:NBIX opened at $92.49 on Friday. The stock has a market capitalization of $8.35 billion, a PE ratio of -57.09 and a beta of 0.32. The company has a current ratio of 11.06, a quick ratio of 11.06 and a debt-to-equity ratio of 1.03. Neurocrine Biosciences has a 1-year low of $92.60 and a 1-year high of $94.19.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, April 30th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.18). The business had revenue of $71.08 million during the quarter, compared to analysts’ expectations of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same period in the prior year, the company earned ($0.90) earnings per share. analysts forecast that Neurocrine Biosciences will post -0.24 EPS for the current fiscal year.
In other news, CEO Kevin Charles Gorman sold 126,832 shares of the company’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $80.75, for a total value of $10,241,684.00. Following the sale, the chief executive officer now directly owns 473,865 shares of the company’s stock, valued at approximately $38,264,598.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Corinne H. Nevinny sold 5,000 shares of the company’s stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $83.13, for a total transaction of $415,650.00. Following the completion of the sale, the director now directly owns 43,283 shares in the company, valued at $3,598,115.79. The disclosure for this sale can be found here. Insiders sold a total of 207,705 shares of company stock worth $17,485,904 over the last ninety days. Insiders own 4.30% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.